Bio-Path Holdings Inc (BPTH)
2.70
-0.30
(-10.00%)
USD |
NASDAQ |
May 08, 16:00
2.70
0.00 (0.00%)
After-Hours: 18:57
Bio-Path Holdings Research and Development Expense (Quarterly): 2.276M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.276M |
| September 30, 2023 | 2.292M |
| June 30, 2023 | 3.051M |
| March 31, 2023 | 3.989M |
| December 31, 2022 | 2.863M |
| September 30, 2022 | 2.353M |
| June 30, 2022 | 1.851M |
| March 31, 2022 | 2.098M |
| December 31, 2021 | 2.908M |
| September 30, 2021 | 0.981M |
| June 30, 2021 | 0.76M |
| March 31, 2021 | 1.261M |
| December 31, 2020 | 1.54M |
| September 30, 2020 | 2.00M |
| June 30, 2020 | 1.03M |
| March 31, 2020 | 2.008M |
| December 31, 2019 | 1.289M |
| September 30, 2019 | 1.375M |
| June 30, 2019 | 1.523M |
| March 31, 2019 | 0.398M |
| December 31, 2018 | 0.502M |
| September 30, 2018 | 2.342M |
| June 30, 2018 | 0.827M |
| March 31, 2018 | 0.932M |
| December 31, 2017 | 1.69M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.534M |
| June 30, 2017 | 1.48M |
| March 31, 2017 | 1.026M |
| December 31, 2016 | 0.954M |
| September 30, 2016 | 2.313M |
| June 30, 2016 | 1.187M |
| March 31, 2016 | 1.02M |
| December 31, 2015 | 0.871M |
| September 30, 2015 | 0.992M |
| June 30, 2015 | 0.532M |
| March 31, 2015 | 0.593M |
| December 31, 2014 | 0.7366M |
| September 30, 2014 | 0.4408M |
| June 30, 2014 | 0.5203M |
| March 31, 2014 | 0.1294M |
| December 31, 2013 | 0.4468M |
| September 30, 2013 | 0.5836M |
| June 30, 2013 | 0.1881M |
| March 31, 2013 | 0.4161M |
| December 31, 2012 | 0.1753M |
| September 30, 2012 | 0.5944M |
| June 30, 2012 | 0.5356M |
| March 31, 2012 | 0.2913M |
| December 31, 2011 | 0.582M |
| September 30, 2011 | 0.1771M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.76M
Minimum
Jun 2021
3.989M
Maximum
Mar 2023
1.971M
Average
2.00M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| INVO Bioscience Inc | 0.0059M |
| EyePoint Pharmaceuticals Inc | 17.95M |
| Hepion Pharmaceuticals Inc | 5.443M |
| Aileron Therapeutics Inc | 1.972M |
| Protara Therapeutics Inc | 7.748M |